Mayflower Group

Mayflower BioVentures is a cell and gene therapy accelerator and venture studio established through a strategic partnership between Mayo Clinic, Hibiscus BioVentures, and Innoforce. The company focuses on identifying and launching independent biotechnology startups built around high-value therapeutic technologies developed within the Mayo Clinic research ecosystem. Mayflower provides the necessary operational, investment, and manufacturing resources to bridge the gap between academic discovery and clinical development. Its first spin-out, Primera Therapeutics, was launched in collaboration with Cellectis to develop gene-editing platforms for mitochondrial diseases. The group aims to advance a diverse pipeline of regenerative medicines, including stem cell and gene therapies, to address significant unmet patient needs.